78996-69-7

Basic information

• Product Name: O-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl) bis(aziridin-1-yl)phosphinothioate
• Synonyms: phosphinothioic acid, P,P-bis(1-aziridinyl)-, O-(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl) ester
• CAS NO: 78996-69-7
• Molecular Formula: C₁₃H₂₆N₃O₂PS
• Molecular Weight: 319.4032
• Mol File: 78996-69-7.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 403.8°C at 760 mmHg
• Flash Point: 198°C
• Density: 1.3g/cm³
• Vapor Pressure: 1.19E-07mmHg at 25°C
• Refractive Index: 1.607
• CAS DataBase Reference: O-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl) bis(aziridin-1-yl)phosphinothioate(CAS DataBase Reference)
• NIST Chemistry Reference: O-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl) bis(aziridin-1-yl)phosphinothioate(78996-69-7)
• EPA Substance Registry System: O-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl) bis(aziridin-1-yl)phosphinothioate(78996-69-7)

Safety Data

• Hazardous Substances Data: 78996-69-7(Hazardous Substances Data)

Upstream product

• 51526-59-1 1-oxyl-2,2,6,6-tetramethyl-4-piperidyl-N,N;N',N'-bis(ethylene)-phosphorodiamidothioate 

Relevant articles and documents

In the Search for New Anticancer Drugs. 9. Synthesis and Anticancer Activity of Spin-Labeled Analogues of N,N:N',N':N'',N''-Tri-1,2-ethanediylphosphoric Triamide and N,N:N',N':N'',N''-Tri-1,2-ethanediylphosphorothioic Triamide

A number of N,N:N',N':N'',N''-tri-1,2-ethanediylphosphoric triamide (TEPA) and N,N:N',N':N'',N''-tri-1,2-ethanediylphosphorothioic triamide (thio-TEPA) derivatives containing either two aziridine moieties (1a) or two (2-chloroethyl)amino functions (1b) and either a 2,2,6,6-tetramethylpiperidine, 1-oxy-2,2,6,6-tetramethylpiperidine or 1-hydroxy-2,2,6,6-tetramethylpiperidine component were synthesized and tested against lymphocytic leukemia P388 in mice.In a structure-activity comparison it was found that at optimum dose all compounds containing the nitroxyl radical were more active than the corresponding hydroxylamine derivatives.The open-chain compounds (1b) were less active than the corresponding aziridine ring compounds (1a).The replacement of the X = bridge in 1a with the X = N(CH3) group resulted in lowering of the anticancer activity.